Parkinson’s Research News

Newsfeed:

  • Growth Factors and Parkinson’s Disease – Where Next?
    “There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more
    Source: IOS PressPublished on 2020-06-04By Carmel McNamara
  • Growth Factors and Parkinson’s Disease – Where Next?
    “There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more
    Source: IOS PressPublished on 2020-06-04By Carmel McNamara
  • Growth Factors and Parkinson’s Disease – Where Next?
    “There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more
    Source: IOS PressPublished on 2020-06-04By Carmel McNamara
  • Growth Factors and Parkinson’s Disease – Where Next?
    “There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more
    Source: IOS PressPublished on 2020-06-04By Carmel McNamara
  • Growth Factors and Parkinson’s Disease – Where Next?
    “There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more
    Source: IOS PressPublished on 2020-06-04By Carmel McNamara
  • Growth Factors and Parkinson’s Disease – Where Next?
    “There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more
    Source: IOS PressPublished on 2020-06-04By Carmel McNamara
  • COVID-19 May Compound the Social and Economic Burdens of Parkinson’s Disease
    The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more
    Source: IOS PressPublished on 2020-05-12By Carmel McNamara
  • COVID-19 May Compound the Social and Economic Burdens of Parkinson’s Disease
    The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more
    Source: IOS PressPublished on 2020-05-12By Carmel McNamara
  • COVID-19 May Compound the Social and Economic Burdens of Parkinson’s Disease
    The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more
    Source: IOS PressPublished on 2020-05-12By Carmel McNamara
  • COVID-19 May Compound the Social and Economic Burdens of Parkinson’s Disease
    The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more
    Source: IOS PressPublished on 2020-05-12By Carmel McNamara
  • COVID-19 May Compound the Social and Economic Burdens of Parkinson’s Disease
    The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more
    Source: IOS PressPublished on 2020-05-12By Carmel McNamara
  • COVID-19 May Compound the Social and Economic Burdens of Parkinson’s Disease
    The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more
    Source: IOS PressPublished on 2020-05-12By Carmel McNamara
  • COVID-19 May Compound the Social and Economic Burdens of Parkinson’s Disease
    The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more
    Source: IOS PressPublished on 2020-05-12By Carmel McNamara
  • COVID-19 May Compound the Social and Economic Burdens of Parkinson’s Disease
    The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more
    Source: IOS PressPublished on 2020-05-12By Carmel McNamara
  • New Trial Platform Could Accelerate Finding a Cure for Parkinson’s Disease
    Many potential disease-modifying therapies have been identified as suitable for clinical evaluation in PD. Each potential cure for PD has to go through three clinical trial phases to test its safety, whether it shows signs of improving PD, and whether there is any meaningful benefit to people with PD. Running a clinical trial is a huge logistical, costly, and time-consuming ... read more
    Source: IOS PressPublished on 2020-05-06By Carmel McNamara
  • New Trial Platform Could Accelerate Finding a Cure for Parkinson’s Disease
    Many potential disease-modifying therapies have been identified as suitable for clinical evaluation in PD. Each potential cure for PD has to go through three clinical trial phases to test its safety, whether it shows signs of improving PD, and whether there is any meaningful benefit to people with PD. Running a clinical trial is a huge logistical, costly, and time-consuming ... read more
    Source: IOS PressPublished on 2020-05-06By Carmel McNamara
  • New Trial Platform Could Accelerate Finding a Cure for Parkinson’s Disease
    Many potential disease-modifying therapies have been identified as suitable for clinical evaluation in PD. Each potential cure for PD has to go through three clinical trial phases to test its safety, whether it shows signs of improving PD, and whether there is any meaningful benefit to people with PD. Running a clinical trial is a huge logistical, costly, and time-consuming ... read more
    Source: IOS PressPublished on 2020-05-06By Carmel McNamara
  • New Trial Platform Could Accelerate Finding a Cure for Parkinson’s Disease
    Many potential disease-modifying therapies have been identified as suitable for clinical evaluation in PD. Each potential cure for PD has to go through three clinical trial phases to test its safety, whether it shows signs of improving PD, and whether there is any meaningful benefit to people with PD. Running a clinical trial is a huge logistical, costly, and time-consuming ... read more
    Source: IOS PressPublished on 2020-05-06By Carmel McNamara
  • New Trial Platform Could Accelerate Finding a Cure for Parkinson’s Disease
    Many potential disease-modifying therapies have been identified as suitable for clinical evaluation in PD. Each potential cure for PD has to go through three clinical trial phases to test its safety, whether it shows signs of improving PD, and whether there is any meaningful benefit to people with PD. Running a clinical trial is a huge logistical, costly, and time-consuming ... read more
    Source: IOS PressPublished on 2020-05-06By Carmel McNamara
  • New Trial Platform Could Accelerate Finding a Cure for Parkinson’s Disease
    Many potential disease-modifying therapies have been identified as suitable for clinical evaluation in PD. Each potential cure for PD has to go through three clinical trial phases to test its safety, whether it shows signs of improving PD, and whether there is any meaningful benefit to people with PD. Running a clinical trial is a huge logistical, costly, and time-consuming ... read more
    Source: IOS PressPublished on 2020-05-06By Carmel McNamara
  • New Trial Platform Could Accelerate Finding a Cure for Parkinson’s Disease
    Many potential disease-modifying therapies have been identified as suitable for clinical evaluation in PD. Each potential cure for PD has to go through three clinical trial phases to test its safety, whether it shows signs of improving PD, and whether there is any meaningful benefit to people with PD. Running a clinical trial is a huge logistical, costly, and time-consuming ... read more
    Source: IOS PressPublished on 2020-05-06By Carmel McNamara
  • New Trial Platform Could Accelerate Finding a Cure for Parkinson’s Disease
    Many potential disease-modifying therapies have been identified as suitable for clinical evaluation in PD. Each potential cure for PD has to go through three clinical trial phases to test its safety, whether it shows signs of improving PD, and whether there is any meaningful benefit to people with PD. Running a clinical trial is a huge logistical, costly, and time-consuming ... read more
    Source: IOS PressPublished on 2020-05-06By Carmel McNamara
  • New Evidence that Higher Caffeine and Urate Levels Are Protective Against Parkinson’s Disease
    “Both caffeine and urate possess neuroprotective properties via adenosine receptor antagonist and antioxidant actions, respectively,” explained lead investigator Rachit Bakshi, PhD, Department of Neurology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA. “They both have protective properties in animal models of PD, raising the possibility of their disease-slowing potential.” Researchers therefore investigated whether these reduced risk factors are ... read more
    Source: IOS PressPublished on 2020-05-05By Carmel McNamara
  • New Evidence that Higher Caffeine and Urate Levels Are Protective Against Parkinson’s Disease
    “Both caffeine and urate possess neuroprotective properties via adenosine receptor antagonist and antioxidant actions, respectively,” explained lead investigator Rachit Bakshi, PhD, Department of Neurology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA. “They both have protective properties in animal models of PD, raising the possibility of their disease-slowing potential.” Researchers therefore investigated whether these reduced risk factors are ... read more
    Source: IOS PressPublished on 2020-05-05By Carmel McNamara
  • New Evidence that Higher Caffeine and Urate Levels Are Protective Against Parkinson’s Disease
    “Both caffeine and urate possess neuroprotective properties via adenosine receptor antagonist and antioxidant actions, respectively,” explained lead investigator Rachit Bakshi, PhD, Department of Neurology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA. “They both have protective properties in animal models of PD, raising the possibility of their disease-slowing potential.” Researchers therefore investigated whether these reduced risk factors are ... read more
    Source: IOS PressPublished on 2020-05-05By Carmel McNamara
1 2 3 84